Revance Therapeutics Inc (RVNC) : Nottingham Advisors reduced its stake in Revance Therapeutics Inc by 11.0% during the most recent quarter end. The investment management company now holds a total of 16,312 shares of Revance Therapeutics Inc which is valued at $242,886 after selling 2,016 shares in Revance Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Revance Therapeutics Inc makes up approximately 0.04% of Nottingham Advisors’s portfolio.
Other Hedge Funds, Including , Dekabank Deutsche Girozentrale sold out all of its stake in RVNC during the most recent quarter. The investment firm sold 13,600 shares of RVNC which is valued $187,952. Rothschild Asset Management Inc added RVNC to its portfolio by purchasing 10,539 company shares during the most recent quarter which is valued at $147,651.
Revance Therapeutics Inc opened for trading at $14.78 and hit $15.14 on the upside on Monday, eventually ending the session at $15, with a gain of 1.69% or 0.25 points. The heightened volatility saw the trading volume jump to 94,110 shares. Company has a market cap of $427 M.
On the company’s financial health, Revance Therapeutics Inc reported $-0.88 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.86. The company had revenue of $.80 million for the quarter, compared to analysts expectations of $.06 million.
Many Wall Street Analysts have commented on Revance Therapeutics Inc. Revance Therapeutics Inc was Downgraded by Brean Capital to ” Hold” on Jun 14, 2016. Shares were Reiterated by Piper Jaffray on Jun 14, 2016 to “Overweight” and Lowered the Price Target to $ 35 from a previous price target of $54 .Shares were Reiterated by SunTrust on Jun 14, 2016 to “Buy” and Lowered the Price Target to $ 22 from a previous price target of $46 .
Revance Therapeutics Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on the development manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through two dose formulations topical product candidate RT001 and injectable product candidate RT002. RT001 is a non-injectable dose form. RT001 is being studied for aesthetic indications such as crow’s feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). It is in a Phase III development program of RT001 in North America for the treatment of crow’s feet lines. RT002 is an injectable formulation of botulinum toxin designed to be targeted and longer lasting. RT002 is being studied for aesthetic indications such as glabellar (frown) lines and therapeutic uses such as muscle movement disorders.